InterPAD - DETAILS

Trifluridine, TRIFLUOROTHYMIDINE, 70-00-8, Viroptic, 5-Trifluorothymidine, Trifluoromethyldeoxyuridine, F3DThd, Trifluridina, Trifluridinum, Virophta, 5-(Trifluoromethyl)deoxyuridine, F3TDR, TFDU, 5-Trifluoromethyl-2-deoxyuridine, Trifluorothymine deoxyriboside, 5-Trifluoromethyl-2'-deoxyuridine, Trifluridinum [INN-Latin], Trifluridina [INN-Spanish], 2'-Deoxy-5-trifluoromethyluridine, 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione, 5-Trifluoro-2'-deoxythymidine, alpha,alpha,alpha-Trifluorothymidine, CCRIS 2348, Trifluridine (Viroptic), 2'-Deoxy-5-(trifluoromethyl)uridine, Thymidine, alpha,alpha,alpha-trifluoro-, Uridine, 2'-deoxy-5-(trifluoromethyl)-, UNII-RMW9V5RW38, EINECS 200-722-8, F3T, RMW9V5RW38, NSC 75520, NSC 529182, BRN 0568095, DTXSID4046602, CHEBI:75179, HSDB 8126, MFCD00006534, NSC-75520, NSC-529182, CHEMBL1129, MLS000028361, Trifluridine [USAN:USP:INN], DTXCID2026602, NSC75520, 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione, 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-5-(trifluoromethyl)-, TAS-102 COMPONENT TRIFLURIDINE, S-95005 COMPONENT TRIFLURIDINE, Fluridine, SMR000058583, Trifluridinum (INN-Latin), Trifluridina (INN-Spanish), TRIFLURIDINE (MART.), TRIFLURIDINE [MART.], 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione, TRIFLURIDINE (USP-RS), TRIFLURIDINE [USP-RS], Trifluridine (USAN:USP:INN), TRIFLURIDINE (EP MONOGRAPH), TRIFLURIDINE [EP MONOGRAPH], TRIFLURIDINE (USP MONOGRAPH), TRIFLURIDINE [USP MONOGRAPH], 5-(Trifluoromethyl)-2'-deoxyuridine, CF3dUrd, Viroptic (TN), Trifluridin, triflorothymidine, NSC529182, 5 Trifluoromethyl 2' deoxyuridine, CAS-70-00-8, NCGC00166323-01, HS-0007, Trifluridinum (Latin), Opera_ID_1810, 5-Trifluoromethylthymidine, TRIFLURIDINE [MI], TRIFLURIDINE [INN], TRIFLURIDINE [JAN], Trifluoromethyl Deoxyuridine, TRIFLURIDINE [USAN], cid_6256, SCHEMBL3479, TRIFLURIDINE [VANDF], MLS001148248, MLS006010219, TRIFLURIDINE [WHO-DD], Trifluridine (JAN/USP/INN), GTPL8697, cid_6708818, S01AD02, HMS2233N19, HMS3715C14, TRIFLURIDINE [ORANGE BOOK], 5-trifluoromethyl-2''-deoxyuridine, BCP09147, HY-A0061, Tox21_112411, BDBM50132298, Trifluorothymidine, >=99% (HPLC), AKOS015919482, Tox21_112411_1, CCG-221056, CS-1602, DB00432, TRIFLURIDINE COMPONENT OF LONSURF, NCGC00166323-02, NCGC00166323-16, 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione, BP-58659, SRI-10817-12, SRI-10817_14, AM20100660, FT-0612140, S1778, SW199522-2, T2511, D00391, Thymidine, .alpha.,.alpha.,.alpha.-trifluoro-, A836733, EN300-24409722, SR-01000721911, J-700255, J-700357, Q2359590, SR-01000721911-2, BRD-K03243820-001-12-1, BRD-K03243820-001-25-3, Trifluridine, British Pharmacopoeia (BP) Reference Standard, Trifluridine;FTD;5-Trifluorothymidine;NSC 529182;NSC 75520, Trifluridine, United States Pharmacopeia (USP) Reference Standard, 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione, 1-((2R,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-trifluoromethyl-1H-pyrimidine-2,4-dione

Name	Trifluridine
PubChem CID	6256
Molecular Weight	296.20g/mol
Synonyms	Trifluridine, TRIFLUOROTHYMIDINE, 70-00-8, Viroptic, 5-Trifluorothymidine, Trifluoromethyldeoxyuridine, F3DThd, Trifluridina, Trifluridinum, Virophta, 5-(Trifluoromethyl)deoxyuridine, F3TDR, TFDU, 5-Trifluoromethyl-2-deoxyuridine, Trifluorothymine deoxyriboside, 5-Trifluoromethyl-2'-deoxyuridine, Trifluridinum [INN-Latin], Trifluridina [INN-Spanish], 2'-Deoxy-5-trifluoromethyluridine, 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione, 5-Trifluoro-2'-deoxythymidine, alpha,alpha,alpha-Trifluorothymidine, CCRIS 2348, Trifluridine (Viroptic), 2'-Deoxy-5-(trifluoromethyl)uridine, Thymidine, alpha,alpha,alpha-trifluoro-, Uridine, 2'-deoxy-5-(trifluoromethyl)-, UNII-RMW9V5RW38, EINECS 200-722-8, F3T, RMW9V5RW38, NSC 75520, NSC 529182, BRN 0568095, DTXSID4046602, CHEBI:75179, HSDB 8126, MFCD00006534, NSC-75520, NSC-529182, CHEMBL1129, MLS000028361, Trifluridine [USAN:USP:INN], DTXCID2026602, NSC75520, 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione, 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-5-(trifluoromethyl)-, TAS-102 COMPONENT TRIFLURIDINE, S-95005 COMPONENT TRIFLURIDINE, Fluridine, SMR000058583, Trifluridinum (INN-Latin), Trifluridina (INN-Spanish), TRIFLURIDINE (MART.), TRIFLURIDINE [MART.], 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione, TRIFLURIDINE (USP-RS), TRIFLURIDINE [USP-RS], Trifluridine (USAN:USP:INN), TRIFLURIDINE (EP MONOGRAPH), TRIFLURIDINE [EP MONOGRAPH], TRIFLURIDINE (USP MONOGRAPH), TRIFLURIDINE [USP MONOGRAPH], 5-(Trifluoromethyl)-2'-deoxyuridine, CF3dUrd, Viroptic (TN), Trifluridin, triflorothymidine, NSC529182, 5 Trifluoromethyl 2' deoxyuridine, CAS-70-00-8, NCGC00166323-01, HS-0007, Trifluridinum (Latin), Opera_ID_1810, 5-Trifluoromethylthymidine, TRIFLURIDINE [MI], TRIFLURIDINE [INN], TRIFLURIDINE [JAN], Trifluoromethyl Deoxyuridine, TRIFLURIDINE [USAN], cid_6256, SCHEMBL3479, TRIFLURIDINE [VANDF], MLS001148248, MLS006010219, TRIFLURIDINE [WHO-DD], Trifluridine (JAN/USP/INN), GTPL8697, cid_6708818, S01AD02, HMS2233N19, HMS3715C14, TRIFLURIDINE [ORANGE BOOK], 5-trifluoromethyl-2''-deoxyuridine, BCP09147, HY-A0061, Tox21_112411, BDBM50132298, Trifluorothymidine, >=99% (HPLC), AKOS015919482, Tox21_112411_1, CCG-221056, CS-1602, DB00432, TRIFLURIDINE COMPONENT OF LONSURF, NCGC00166323-02, NCGC00166323-16, 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione, BP-58659, SRI-10817-12, SRI-10817_14, AM20100660, FT-0612140, S1778, SW199522-2, T2511, D00391, Thymidine, .alpha.,.alpha.,.alpha.-trifluoro-, A836733, EN300-24409722, SR-01000721911, J-700255, J-700357, Q2359590, SR-01000721911-2, BRD-K03243820-001-12-1, BRD-K03243820-001-25-3, Trifluridine, British Pharmacopoeia (BP) Reference Standard, Trifluridine;FTD;5-Trifluorothymidine;NSC 529182;NSC 75520, Trifluridine, United States Pharmacopeia (USP) Reference Standard, 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione, 1-((2R,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-trifluoromethyl-1H-pyrimidine-2,4-dione
Drug Type	Small molecule
Formula	C₁₀H₁₁F₃N₂O₅
SMILES	C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
InChI	1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
InChIKey	VSQQQLOSPVPRAZ-RRKCRQDMSA-N
CAS Number	70-00-8
ChEMBL ID	CHEMBL1129
ChEBI ID	CHEBI:75179
TTD ID	D05RHI
Drug Bank ID	DB00432
KEGG ID	D00391
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Cryptotanshinone, Trifluridine
Partner Name	Cryptotanshinone
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CASP9	hsa842
	Up-regulation	Expression	CCNB1	hsa891
	Down-regulation	Phosphorylation	JAK2	hsa3717
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	HGC-27	Gastric carcinoma	Homo sapiens (Human)	CVCL_1279
In Vitro Model	AGS	Gastric adenocarcinoma	Homo sapiens (Human)	CVCL_0139
In Vivo Model	After adaptive feeding for 1 week, 100 µl cell suspension of HGC-27 cells was injected into the axilla of the nude mice with a density of 4×10⁷ cells/ml.
Result	FTD combined with CTS has a synergistic anti-gastric cancer effect as shown by in vitro and in vivo experiments, and the combined treatment of FTD and CTS will be a promising treatment option for advanced gastric cancer.